<DOC>
	<DOCNO>NCT01757288</DOCNO>
	<brief_summary>The investigator propose phase I/II study use weekly Nab-Paclitaxel ( Abraxane ) carboplatin concurrent radiation local-regionally advanced lung cancer . There publish human study combine Nab-Paclitaxel ( Abraxane ) radiation . The investigator first confirm tolerate dose ( TD ) concurrent Nab-Paclitaxel ( Abraxane ) 50mg/m2 , begin enrol patient phase II component use either Nab-Paclitaxel ( Abraxane ) TD carboplatin concurrent daily radiation paclitaxel carboplatin concurrent daily radiation .</brief_summary>
	<brief_title>Phase I/II NabPaclitaxel , Paclitaxel &amp; Carboplatin w RTX Followed Consolidation Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically document NSCLC ; Patients must M0 . Patients T1T2 N2 T3N12 eligible , inoperable . Patients T4 N T N2 N3 disease eligible unresectable . Patients tumor adjacent vertebral body eligible long gross disease encompass radiation boost field . The boost volume must limit &lt; 50 % ipsilateral lung volume . Patients Zubrod performance status 01 Adequate hematologic function FEV1 ≥ 1200 cc ≥ 50 % predict Prior systemic chemotherapy ( lung cancer ) and/or thoracic/neck radiotherapy reason and/or surgical resection present cancer Exudative , bloody , cytologically malignant effusion Prior therapy molecular target drug ( lung cancer ) Active pulmonary infection responsive conventional antibiotic Clinically significant cardiovascular event ( e.g . myocardial infarction , superior vena cava syndrome ( SVC ) , New York Heart Association ( NYHA ) classification heart disease &gt; 2 ( see Appendix B ) within 3 month entry ; presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia . Patients &gt; grade 1 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER</keyword>
</DOC>